

Supplementary Table 3. Subgroup analyses for the risk of total stroke diagnosed only by inpatient and emergency according to baseline hemoglobin A1c levels in patients with type 2 diabetes

Variable	No. of patients	Hemoglobin A1c (%)						P for trend
		<6.0	6.0–6.9	7.0–7.9	8.0–8.9	9.0–9.9	≥10	
Age (yr)								
<60	19,414	1.23 (0.78–1.93)	1.00	1.09 (0.54–1.46)	1.23 (0.73–2.06)	1.81 (1.11–2.96)	1.55 (1.02–2.34)	0.033
≥60	40,095	1.25 (1.05–1.49)	1.00	1.39 (1.18–1.65)	1.40 (1.13–1.74)	1.42 (1.08–1.88)	1.74 (1.40–2.17)	<0.001
Sex								
Man	28,239	1.20 (1.01–1.53)	1.00	1.39 (1.10–1.76)	1.38 (1.03–1.85)	1.30 (0.89–1.91)	1.87 (1.39–2.51)	0.001
Women	31,270	1.39 (1.11–1.73)	1.00	1.31 (1.05–1.63)	1.47 (1.12–1.93)	1.99 (1.46–2.70)	1.92 (1.48–2.50)	<0.001
Race								
African Americans	24,140	1.31 (1.01–1.72)	1.00	1.18 (0.91–1.53)	1.36 (1.00–1.85)	1.74 (1.24–2.45)	1.79 (1.35–2.37)	<0.001
Whites	35,369	1.30 (1.06–1.60)	1.00	1.47 (1.20–1.79)	1.49 (1.15–1.94)	1.56 (1.11–2.19)	2.00 (1.52–2.64)	<0.001
Body mass index (kg/m²)								
<30	22,847	1.29 (1.05–1.59)	1.00	1.38 (1.11–1.72)	1.65 (1.26–2.16)	1.67 (1.18–2.35)	1.85 (1.39–2.46)	<0.001
≥30	36,662	1.40 (1.08–1.82)	1.00	1.29 (1.02–1.63)	1.18 (0.88–1.59)	1.62 (1.16–2.25)	1.93 (1.47–2.53)	<0.001
Smoking status								
Never smoking	47,965	1.27 (1.05–1.54)	1.00	1.50 (1.26–1.80)	1.61 (1.29–2.01)	1.77 (1.35–2.33)	1.94 (1.56–2.43)	<0.001
Past and current smoking	11,544	1.41 (1.02–1.94)	1.00	1.02 (0.65–1.34)	1.26 (0.61–1.55)	1.47 (0.88–2.45)	1.89 (1.25–2.86)	0.012
Using antidiabetic medications*								
No	16,393	1.06 (0.82–1.36)	1.00	1.33 (0.94–1.88)	1.43 (0.86–2.36)	1.63 (0.85–3.13)	1.07 (0.84–2.02)	0.246
Yes	43,116	1.54 (1.24–1.91)	1.00	1.39 (1.16–1.67)	1.47 (1.18–1.84)	1.71 (1.32–2.21)	2.01 (1.63–2.48)	<0.001
Insulin or sulfonylurea	17,691	1.44 (1.12–1.86)	1.00	1.12 (0.91–1.38)	1.16 (1.02–1.48)	1.33 (1.01–1.75)	1.49 (1.18–1.87)	0.013
Others	25,425	1.28 (1.03–1.58)	1.00	1.38 (1.06–1.79)	1.38 (0.91–2.09)	1.43 (0.79–2.59)	1.12 (0.60–2.08)	0.114
Using lipid-lowering medications*								
No	24,027	1.31 (1.01–1.73)	1.00	1.37 (1.02–1.83)	1.26 (1.01–1.85)	2.01 (1.34–3.02)	1.73 (0.94–3.24)	0.013
Yes	35,482	1.30 (1.06–1.60)	1.00	1.38 (1.14–1.68)	1.56 (1.23–1.98)	1.57 (1.17–2.11)	2.27 (1.80–2.85)	<0.001
Using antihypertensive medications*								
No	14,069	2.00 (1.22–3.29)	1.00	1.88 (1.13–3.11)	2.06 (1.10–3.86)	2.53 (1.25–5.10)	2.25 (1.21–4.17)	0.021
Yes	45,440	1.24 (1.04–1.48)	1.00	1.30 (1.10–1.54)	1.38 (1.12–1.71)	1.60 (1.24–2.06)	1.90 (1.54–2.33)	<0.001
Using antiplatelet or anticoagulant drugs*								
No	47,384	1.50 (1.17–1.93)	1.00	1.54 (1.22–1.94)	1.82 (1.37–2.42)	2.40 (1.71–3.37)	2.55 (1.91–3.41)	<0.001
Yes	12,125	1.19 (0.96–1.49)	1.00	1.18 (0.95–1.47)	1.14 (0.86–1.51)	1.17 (0.84–1.64)	1.48 (1.13–1.92)	0.072
Presence of atrial fibrillation*								
No	52,065	1.45 (1.17–1.81)	1.00	1.42 (1.17–1.74)	1.51 (1.18–1.93)	1.98 (1.51–2.59)	1.91 (1.51–2.41)	<0.001
Yes	7,444	1.11 (0.87–1.44)	1.00	1.25 (0.96–1.64)	1.28 (0.90–1.81)	1.30 (0.88–1.57)	2.01 (1.40–2.87)	0.002

Values are presented as hazard ratio (95% confidence interval) unless otherwise indicated. All hazard ratios were adjusted for age, sex, race, body mass index, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, estimated glomerular filtration rate, smoking, insurance type, use of antihypertensive drugs, use of glucose lowering drugs, use of lipid-lowering drugs, use of antiplatelet or anticoagulant drugs, and presence of atrial fibrillation other than the variable for stratification.

*P for interaction <0.05.